REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

26 Jun 2025 05:40:56 By Nasdaq GlobeNewswire

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

25 Jun 2025 13:17:23 By Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

05 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

02 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in Upcoming Investor Conferences in May 2025

20 May 2025 05:00:01 By Nasdaq GlobeNewswire

Reviva to Participate in the A.G.P. Healthcare Company Showcase

13 May 2025 05:00:01 By Nasdaq GlobeNewswire

Reviva to Participate in the Citizens Life Sciences Conference

29 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

24 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

31 Mar 2025 13:05:15 By Nasdaq GlobeNewswire

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

30 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the 2025 BIO CEO & Investor Conference

30 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

07 Jan 2025 05:00:01 By Nasdaq GlobeNewswire

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

16 Dec 2024 19:25:45 By Nasdaq GlobeNewswire

Reviva Announces Proposed Public Offering

16 Dec 2024 14:18:02 By Nasdaq GlobeNewswire

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

16 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 14:25:00 By Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

12 Nov 2024 05:00:02 By Nasdaq GlobeNewswire

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

06 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Reviva to Participate in the UBS Global Healthcare Conference

31 Oct 2024 05:00:00 By Nasdaq GlobeNewswire